Recent Updates
Recently added Catalysts
FBIO Positive Sentiment Score: 75/100

Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Key Takeaway: Fortress Biotech, Inc. (Nasdaq: FBIO) has announced a corporate overview presentation by its CEO, Lindsay A. Rosenwald, at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will be available for on-demand viewing starting on September 9, 2024. Fortress, which has seven marketed pharmaceutical products and numerous programs in development, is focused on enhancing shareholder value through strategic acquisitions and partnerships in sectors such as oncology and gene therapy.

Market Sentiment Analysis

POSITIVE FACTORS

  • Fortress Biotech is presenting at a prominent investment conference.
  • The company has a diversified pipeline with over 20 programs in development.
  • Partnerships with leading institutions enhance its development potential.

Full Press Release Details

MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will be available for on-demand viewing by conference attendees starting on September 9, 2024, at 7:00 a.m. ET. The Company will also attend one-on-one meetings during the conference.
About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue. The company has seven marketed prescription pharmaceutical products and over 20 programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Fred Hutchinson Cancer Center, Nationwide Children’s Hospital and Sentynl. For more information, visit www.fortressbiotech.com.
Fortress Biotech, Inc.
Media Relations Contact:

Tags

HC Wainwright Conference

Frequently Asked Questions

What is Fortress Biotech, Inc. known for?

Fortress Biotech, Inc. is known for acquiring and advancing biopharmaceutical assets.

When will Fortress's conference presentation be available?

The presentation will be available on September 9, 2024, at 7:00 a.m. ET.

How many pharmaceutical products does Fortress have?

Fortress has seven marketed prescription pharmaceutical products.

What areas do Fortress's product candidates cover?

Their product candidates span oncology, rare diseases, and gene therapy.

Who is presenting at the H.C. Wainwright Conference?

Lindsay A. Rosenwald, M.D. will present a corporate overview.

Last updated: Sep 4, 2024